Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Discovery & Development Drug Discovery, Technology and Equipment, Digital Technologies

Connecting the Data

Companies are increasingly investing in AI, and machine and deep learning to open up new routes to innovation, but the technology is new and the data available in life sciences is vast – and many are not seeing the insights from AI that they expected. Elsevier has developed a new AI platform called Entellect that is specifically designed to cope with scientific data. The platform can contextualize and connect drug, target, and disease data. We speak with Tim Miller, VP Elsevier, Life Sciences Platform Solutions, to find out more.

How can using data more efficiently aid drug development?

Every drug development program generates massive amounts of data – and hidden within that data can be a new clue that might start a new drug program, or halt a drug program otherwise doomed to fail expensively. But so much of a data scientist’s time is currently taken up with tasks such as cleansing, integrating and formatting data. Simply making data management more efficient could make a huge difference. Data is the lifeblood of life sciences R&D today and removing the obstacles to using it is critical in supporting the industry to deliver positive outcomes for patients. Whether realizing the full potential of precision medicine, identifying drug candidates for repurposing in rare disease treatment, or analyzing the safety and efficacy profiles of compounds in early R&D – the potential benefits through the use of deep learning platforms are significant.

What are the challenges of using AI in life sciences?

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at.

From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register